Credit: Getty Images. The incidence and prevalence of a first-ever spontaneous pneumothorax in patients with chronic obstructive pulmonary disease (COPD) and emphysema are increased significantly in ...

More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This chronic lung ...

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

A CT scan of healthy lungs looks typical in size with no inflammation, allowing the diaphragm to dome. Lungs with emphysema can look overinflated, with muscle loss, making the diaphragm misshapen. The ...

Spectrum Health is one of the first hospitals in Michigan to offer a novel treatment for emphysema. The treatment uses the Zephyr® Valve system, an FDA-approved minimally invasive procedure requiring ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In those with and those without emphysema, patients ...

Emphysema is a type of chronic obstructive pulmonary disease involving damage to the air sacs (alveoli) in the lungs. As a result, your body does not get the oxygen it needs. Emphysema makes it hard ...

Emphysema is a disease that makes it hard for you to catch your breath. Stage 4 means your emphysema is advanced and that your breathing is very severely affected. At this stage, smoking or other ...

Emphysema happens when smoke from tobacco or other pollutants slowly damage the tiny air sacs in your lungs called alveoli. Normally, some 300 million alveoli help bring oxygen into your body and get ...

Please provide your email address to receive an email when new articles are posted on . Adults with a low-dose CT scan between June 2000 and December 2008 were followed for a median of 23.3 years.

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...